Tag Archives: AMEX

Warren Buffett's Top 5 Bank Stocks

By John Grgurich, The Motley Fool

Filed under:

The catchphrase used to be, “When E.F. Hutton talks, people listen.” Now when it comes to financial advice, you could easily insert the name Warren Buffet.

Does the Sage of Omaha need an introduction? Just in case, according to Forbes Buffet is the fourth-richest man in the world. As a general rule, he got that way by investing in companies he can easily get his head around, have powerful brands, have wide moats, and are undervalued.

Through his company, Berkshire Hathaway , Buffet invests in a little bit of everything, including bank stocks. Here are Berkshire’s top five bank holdings, along with a quick explanation of why Buffet and his team might like them:

5. M&T Bank
At around $551 million, M&T is Berkshire’s smallest bank holding. It’s a regional bank assets of about $81 billion. Not big by JPMorgan Chase standards, but big enough to do serious business and potentially exhibit serious growth, which it’s already done.

In the past year, M&T’s share price has increased by 18.68%. The bank also has a price-to-book ratio of 1.41: indicating it’s not a screaming value, but also that the bank certainly isn’t overvalued.

Small enough to get your head around, but big enough to make things happen, all at a reasonable valuation: From a Buffet perspective, what’s not to like?

4. Bank of New York Mellon
At around $555 million — just slightly more than M&T — BNY Mellon is Berkshire’s next biggest bank holding. But BNY is a big bank, the country’s eighth largest. It has nearly $360 billion in assets on its balance sheet. 

That said, it’s run rather conservatively. Most of the business it does is with other banks, all of which is conducted in a straightforward manner. Ever read about BNY in the news, getting fined left and right by regulators? Or being sued by angry investors?

No, BNY is a throwback to the days when banks were beautifully boring, yet profitable. BNY has returned 14.64% to investors in the past year, and the P/B of is 0.93: all right up Buffet’s alley.

3. U.S. Bancorp
At a little over $2 billion, U.S. Bancorp is Buffet’s next biggest bank holding. Like BNY Mellon, it’s a big bank, with assets of around $353 billion. 

Also like BNY Mellon, U.S. Bancorp is another bank that — for all its immensity — also operates relatively under-the-radar. And while its P/B is little high — 1.83 — its return on equity is a fabulous 14.59%, which means it’s out there making good on Buffet’s investing dollars.

In the past year, it’s only returned 4.86% of positive share-price growth, but Buffet doesn’t necessarily go for high-flyers. He’ll typically take steady, low-drama growth any day of the week.

2. American Express
This is a bit of cheat. AMEX isn’t a bank, but it’s a big financial services company that Buffet likes enough to hold more than $10 billion of.

AMEX is a classic American company that’s …read more
Source: FULL ARTICLE at DailyFinance

What Is This CEO Doing to Earn $450 Per Hour?

By Brian Orelli, The Motley Fool

GERN Chart

Filed under:

The questions from analysts at the end of a company’s conference call typically fall in the softball category. There’s often a lot of backslapping when things go well, “Congrats on the great quarter.” And when things aren’t all right, many analysts tiptoe around the issue, asking necessary questions to understand where things went wrong, but avoiding calling out management as part of the problem.

Call me cynical, but I think there’s a clear reason for the buddy-buddy relationship. Analysts work for investment banks that link companies with investors for secondary offerings. If analysts aren’t nice, their co-workers on the banking side aren’t going to get any business.

The one that got through…
So it was rather refreshing this week when Geron let Robert Lawson, an analyst from Catoosa Fund, ask a few questions at the end of its fourth-quarter earnings conference call this week. Presumably without any need for love from Geron’s management, Lawson was free to say whatever he wanted.

And, boy, did he let management have it.

First, a little background
If you haven’t been following the company, let’s get you up to date quickly.

Geron is most famous for being a stem-cell company, but the biotech dropped the program in late 2011. I thought it was a pretty good move considering the program was expensive and risky. The biotech had two cancer drugs that were further along. Dropping the stem-cell program allowed the company to conserve cash and focus on drugs that would get to market quicker.

Unfortunately, they blew up. First, imetelstat failed a phase 2 trial in breast cancer. Then GRN1005 failed a trial testing its activity on brain metastases in patients with breast cancer.

The company cut back spending, laying off much of its workforce. Operating expenses fell 37% in the fourth quarter.

The new plan involves focusing on imetelstat in other types of cancer. A phase 2 trial in a blood cancer called essential thrombocythemia came back positive. The company plans to wait for data from an investigator-sponsored trial in another blood disorder called myelofibrosis expected this year before launching its own trial, a prudent move for a drug that’s only batting .500.

Back to our story
So, what’s got Lawton’s feathers ruffled? Since John Scarlett took over as Geron’s CEO and decided to shift directions, shares are down about 40% while the AMEX biotech index is up more than 60%.

GERN data by YCharts.

Despite the poor performance, Lawton claims that Scarlett made $900,000 last year, including a $300,000 bonus. Assuming 40 hours a week with two weeks of vacation, that’s $450 per hour. “I guess, put simply, what are you doing on a daily basis in 2013 to sort of earn your $450 per hour?” Lawton asked on the conference call.

Scarlett pleaded innocent, claiming that he has no control over his pay that’s set by “external advisors and consultants” that use the going rate for a biotech CEO as a guide. Of course, his …read more
Source: FULL ARTICLE at DailyFinance